The latest OS analysis of phase III SOLO1 trial was presented in #ESMO2022 supporting the use of maintenance #olaparib in patients with #BRCA-mutated advanced ovarian cancer after responding to first-line platinum-based chemotherapy. After 7 years of follow-up, the median OS was not reached with olaparib compared with 75.2 months with placebo (HR= 0.55). At 7y, 45.3% of olaparib patients vs 20.6% of placebo pts were alive and had still not received a first subsequent treatment. This data provides the longest f/u for any PARP inhibitor in this setting.